Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling

Hyperactivated RAS drives progression of many human malignancies. However, oncogenic activity of RAS is dependent on simultaneous inactivation of protein phosphatase 2A (PP2A) activity. Although PP2A is known to regulate some of the RAS effector pathways, it has not been systematically assessed how these proteins functionally interact. Here we have analyzed phosphoproteomes regulated by either RAS or PP2A, by phosphopeptide enrichment followed by mass-spectrometry-based label-free quantification. To allow data normalization in situations where depletion of RAS or PP2A inhibitor CIP2A causes a large uni-directional change in the phosphopeptide abundance, we developed a novel normalization strategy, named pairwise normalization. This normalization is based on adjusting phosphopeptide abundances measured before and after the enrichment. The superior performance of the pairwise normalization was verified by various independent methods. Additionally, we demonstrate how the selected normalization method influences the downstream analyses and interpretation of pathway activities. Consequently, bioinformatics analysis of RAS and CIP2A regulated phosphoproteomes revealed a significant overlap in their functional pathways. This is most likely biologically meaningful as we observed a synergistic survival effect between CIP2A and RAS expression as well as KRAS activating mutations in TCGA pan-cancer data set, and synergistic relationship between CIP2A and KRAS depletion in colony growth assays.

[1]  Jukka Westermarck,et al.  ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays , 2014, PloS one.

[2]  Ruedi Aebersold,et al.  Confident site localization using a simulated phosphopeptide spectral library. , 2015, Journal of proteome research.

[3]  M. Copland,et al.  Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. , 2011, Blood.

[4]  J. Downward Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[5]  S. Tuomela,et al.  Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation , 2012, Oncogene.

[6]  S. Gabriel,et al.  Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.

[7]  T. Köcher,et al.  Universal and confident phosphorylation site localization using phosphoRS. , 2011, Journal of proteome research.

[8]  S. Joel,et al.  Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells , 2013, Science Signaling.

[9]  R. Bernards,et al.  Protein phosphatase 2A regulatory subunits and cancer. , 2009, Biochimica et biophysica acta.

[10]  W. Hahn,et al.  Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.

[11]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[12]  J. Eriksson,et al.  In Vivo Identification of Sumoylation Sites by a Signature Tag and Cysteine-targeted Affinity Purification* , 2010, The Journal of Biological Chemistry.

[13]  I. Prior,et al.  Ras isoform abundance and signalling in human cancer cell lines , 2008, Oncogene.

[14]  S. Schreiber,et al.  Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Liu,et al.  CIP2A Is Overexpressed in Gastric Cancer and Its Depletion Leads to Impaired Clonogenicity, Senescence, or Differentiation of Tumor Cells , 2008, Clinical Cancer Research.

[16]  J. Chen,et al.  Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. , 1992, Science.

[17]  D. Haussler,et al.  Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser , 2013, Scientific Reports.

[18]  M. Mumby PP2A: Unveiling a Reluctant Tumor Suppressor , 2007, Cell.

[19]  O. Kallioniemi,et al.  CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes , 2012, Oncogene.

[20]  A. Takai,et al.  Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. , 1988, The Biochemical journal.

[21]  W. Hahn,et al.  Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. , 2003, Cancer cell.

[22]  P. Roepstorff,et al.  Highly Selective Enrichment of Phosphorylated Peptides from Peptide Mixtures Using Titanium Dioxide Microcolumns* , 2005, Molecular & Cellular Proteomics.

[23]  K. Kalland,et al.  KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer , 2012, British Journal of Cancer.

[24]  W. Hahn,et al.  Identification of PP2A complexes and pathways involved in cell transformation. , 2010, Cancer research.

[25]  D. Spandidos,et al.  Mutations and Expression of the ras Family Genes in Leukemias , 1996, Stem cells.

[26]  Yu Xue,et al.  GPS 2.0, a Tool to Predict Kinase-specific Phosphorylation Sites in Hierarchy *S , 2008, Molecular & Cellular Proteomics.

[27]  E. Petricoin,et al.  Discovery of Mouse Spleen Signaling Responses to Anthrax using Label-Free Quantitative Phosphoproteomics via Mass Spectrometry* , 2010, Molecular & Cellular Proteomics.

[28]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[29]  R. Bast,et al.  Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model , 2005, Oncogene.

[30]  Wen-Lian Hsu,et al.  An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. , 2010, Journal of proteome research.

[31]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[32]  L. Jensen,et al.  KinomeXplorer: an integrated platform for kinome biology studies , 2014, Nature Methods.

[33]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[34]  W. Hahn,et al.  PP2A-mediated regulation of Ras signaling in G2 is essential for stable quiescence and normal G1 length. , 2014, Molecular cell.

[35]  O. Jensen Interpreting the protein language using proteomics , 2006, Nature Reviews Molecular Cell Biology.

[36]  Y. Bahk,et al.  A Proteomic approach for protein‐profiling the oncogenic ras induced transformation (H‐, K‐, and N‐Ras) in NIH/3T3 mouse embryonic fibroblasts , 2008, Proteomics.

[37]  J. Blenis,et al.  RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation* , 2007, Journal of Biological Chemistry.

[38]  M. Larsen,et al.  Technologies and challenges in large‐scale phosphoproteomics , 2013, Proteomics.

[39]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[40]  F. Gnad,et al.  Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics* , 2013, Molecular & Cellular Proteomics.

[41]  M. Mann,et al.  Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. , 2014, Cell reports.

[42]  Garry L Corthals,et al.  Reference-facilitated Phosphoproteomics , 2007, Molecular & Cellular Proteomics.

[43]  U. Rapp,et al.  Ras oncogenes and their downstream targets. , 2007, Biochimica et biophysica acta.

[44]  Robert A. Weinberg,et al.  Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation , 2002, Molecular and Cellular Biology.

[45]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[46]  A. Cheng,et al.  CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells , 2010, Oncogene.

[47]  Gregory Stephanopoulos,et al.  Molecular Systems Biology Peer Review Process File Oncogenic K-ras Decouples Glucose and Glutamine Metabolism to Support Cancer Cell Growth Transaction Report , 2022 .

[48]  T. Hunter,et al.  Protein kinase signaling networks in cancer. , 2011, Current opinion in genetics & development.

[49]  B. Hemmings,et al.  Role of protein phosphatase 2A in the regulation of mitogen-activated protein kinase activity in ventricular cardiomyocytes. , 1996, Biochemical and biophysical research communications.

[50]  R. Sears,et al.  CIP2A Inhibits PP2A in Human Malignancies , 2007, Cell.

[51]  W. Hahn,et al.  SV40 small T antigen and PP2A phosphatase in cell transformation , 2008, Cancer and Metastasis Reviews.

[52]  R. Weinberg,et al.  Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.

[53]  P. Cutillas,et al.  Characterization of a TiO2 enrichment method for label-free quantitative phosphoproteomics , 2011, Methods.

[54]  F. Haluska,et al.  Genetic Alterations in Signaling Pathways in Melanoma , 2006, Clinical Cancer Research.

[55]  C. Haglund,et al.  Prognostic role of CIP2A expression in serous ovarian cancer , 2011, British Journal of Cancer.

[56]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[57]  M. Mumby,et al.  The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation , 1993, Cell.

[58]  T. Roberts,et al.  Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner , 2007, Proceedings of the National Academy of Sciences.

[59]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[60]  R. Honkanen,et al.  Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. , 2007, Methods in molecular biology.

[61]  M. Caron,et al.  Quantitative Label-Free Phosphoproteomics Strategy for Multifaceted Experimental Designs , 2011, Analytical chemistry.

[62]  G. Evan,et al.  Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. , 2013, Cancer discovery.

[63]  Ting Wang,et al.  The UCSC Cancer Genomics Browser , 2009, Nature Methods.

[64]  T. Aittokallio,et al.  Phosphoproteomics Combined with Quantitative 14-3-3-affinity Capture Identifies SIRT1 and RAI as Novel Regulators of Cytosolic Double-stranded RNA Recognition Pathway* , 2014, Molecular & Cellular Proteomics.

[65]  S. Elledge,et al.  A quantitative atlas of mitotic phosphorylation , 2008, Proceedings of the National Academy of Sciences.

[66]  A. Heck,et al.  Single-step Enrichment by Ti4+-IMAC and Label-free Quantitation Enables In-depth Monitoring of Phosphorylation Dynamics with High Reproducibility and Temporal Resolution * , 2014, Molecular & Cellular Proteomics.

[67]  T. Hunter,et al.  Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.

[68]  B. Bai,et al.  Proteomics analysis reveals insight into the mechanism of H-Ras-mediated transformation. , 2006, Journal of proteome research.

[69]  W. Hsu,et al.  Phosphoproteomics Identifies Oncogenic Ras Signaling Targets and Their Involvement in Lung Adenocarcinomas , 2011, PloS one.

[70]  F. Porteu,et al.  B56‐containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX‐1 and ERK , 2006, The EMBO journal.

[71]  Andrew R. Jones,et al.  ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.

[72]  K. Lage,et al.  Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues , 2012, Nature Communications.

[73]  J. Yates,et al.  Protein analysis by shotgun/bottom-up proteomics. , 2013, Chemical reviews.

[74]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[75]  Ronald J. Moore,et al.  Applying a targeted label-free approach using LC-MS AMT tags to evaluate changes in protein phosphorylation following phosphatase inhibition. , 2007, Journal of proteome research.

[76]  B. Winblad,et al.  Interactions between glycogen synthase kinase 3beta, protein kinase B, and protein phosphatase 2A in tau phosphorylation in mouse N2a neuroblastoma cells. , 2009, Journal of Alzheimer's disease : JAD.